Clevidipine butyrate: A promising new drug for the management of acute hypertension

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 2, 2010, Pages 281-295

  Bergese, Sergio D ^a   Puente, Erika G ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

Acute severe and perioperative hypertension; Calcium channel blocker; Clevidipine butyrate; Intravenous antihypertensive agent

Indexed keywords

ANTIHYPERTENSIVE AGENT; CLEVIDIPINE; CLEVIDIPINE BUTYRATE; ESMOLOL; FENOLDOPAM; GLYCERYL TRINITRATE; HYDRALAZINE; LABETALOL; NICARDIPINE; NITROPRUSSIDE SODIUM; PLACEBO; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; BLOOD PRESSURE MEASUREMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FEVER; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; ESSENTIAL HYPERTENSION; FLUSHING; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; INFUSION RATE; MORTALITY; NAUSEA; REVIEW; SIDE EFFECT; TREATMENT CONTRAINDICATION; UNSPECIFIED SIDE EFFECT;

ACUTE DISEASE; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CARDIOTONIC AGENTS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HYPERTENSION; PYRIDINES; VASODILATOR AGENTS;

EID: 76749125824     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560903499293     Document Type: Review

References (69)

1. Cutler J, Sorlie P, Wolz M, et al.. Trends in hypertension prevalence, awareness, treatment and control rates in United States adults between 1988 - 1994 and 1999 - 2004. Hypertension 2008;52:818-827
2. Peacock WF, Angeles JE, Soto KM, et al.. Parenteral clevidipine for the acute control of blood pressure in the critically ill patient: a review. Ther Clin Risk Manag 2009;5:627-634
3. Chobania AV, Bakris GL, Black HR, et al.. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003;42:1206-1252
4. Hajjar I, Kotchen TA. Trends and prevalence, awareness, treatment, and control of hypertension in the United States, 1998 - 2000. JAMA 2003;290:199-206
5. Greenland P, Knoll MD, Stamler J, et al.. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA 2003;290:891-897
6. Cherry DK, Hing E, Woodwell DA, et al.. National ambulatory medical care survey: 2006 summary. Natl Health Stat Rep 2008;3:1-39
7. Wilson PW. Established risk factors and coronary artery disease: the Framingham study. Am J Hypertens 1994;7:7-12
8. Levy D, Larson MG, Vasan RS, et al.. The progression from hypertension to congestive heart failure. JAMA 1996;275:1557-1562 (Pubitemid 26154241)
9. Lorell BH, Carabello BA. Left ventricular hypertrophy: pathogenesis, detection, and prognosis. Circulation 2000;102:470-479
10. Staessen JA, Fagard R, Thijs L, et al.. Randomized double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe Trial Investigators. Lancet 1997;350:757-764
11. Thrift AG, McNeill JJ, Forbes A, et al.. Risk factors for cerebral hemorrhage in the era of well-controlled hypertension. Melbourne Risk Factor Study (MERFS) Group. Stroke 1996;27:2020-2025
12. Coresh J, Wei GL, McQuillan G, et al.. Prevelance of high blood pressure and elevated serum creatinine level in the United States: findings from the Third National Health and Nutrition Examination Survey (1988 - 1994). Arch Intern Med 2001;161:1207-1216
13. Hsu CY, McCulloch CE, Darbinian J, et al.. Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease. Arch Intern Med 2005;165:923-928
14. Kaplan NM. Management of hypertensive emergencies. Lancet 1994;344:1335-1338
15. Ahmed ME, Walker JM, Beevers DG, et al.. Lack of difference between malignant and accelerated hypertension. Br Med J 1986;292:235-237
16. Phillips SJ, Whisnant JP. Hypertension and the brain. Arch Intern Med 1992;152:938-945
17. Strandgaard S, Paulson OB. Cerebral blood flow and its pathophysiology in hypertension. Am J Hypertens 1989;2:486-492
18. Grossman E, Messerli FH, Grodzicki T, et al.. Should a moratorium be placed on sublingual nifedipine capsules for hypertensive emergencies or pseudoemergencies? JAMA 1996;276:1328-1331
19. Haas DC, Streeten DHP, Kim RC, et al.. Death from cerebral hypoperfusion during nitroprusside treatment of acute angiotensin-dependent hypertension. Am J Med 1983;75:1071-1076
20. Materson BJ, Reda DJ, Cushman WC, et al.. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. N Engl J Med 1993;328:914-921
21. Eisenberg MJ, Brox A, Bestawros AN. Calcium channel blockers: an update. Am J Med 2004;116:35-43
22. Abernethy DR, Schwartz JB. Calcium-antagonist drugs. N Engl J Med 1999;341:1447-1457
23. Severe symptomless hypertension. Lancet 1989;2:1369-1370
24. Handler J. Hypertensive urgency. J Clin Hypertens 2006;8:61-64
25. Cherney D, Straus S. Management of patients with hypertensive urgencies and emergencies: a systematic review of the literature. J Gen Intern Med 2002;17:937-945
26. Dix P, Howell S. Survey of cancellation rate of hypertensive patients undergoing anaesthesia and elective surgery. Br J Anaesth 2001;86:789-793
27. Wolfsthal SD. Is blood pressure control necessary before surgery? Med Clin North Am 1993;77:349-363
28. Goldman L, Caldera DL. Risks of general anesthesia and elective operation in the hypertensive patient. Anesthesiology 1979;50:285-292
29. Rhoney D, Peacock WF. Intravenous therapy for hypertensive emergencies, part 1. Am J Health Syst Pharm 2009;66:1343-1352
30. Rhoney D, Peacock WF. Intravenous therapy for hypertensive emergencies, part 2. Am J Health Syst Pharm 2009;66:1448-1457
31. Varon J. Treatment of acute severe hypertension: current and newer agents. Drugs 2008;68:283-297
32. Varon J, Marik PE. Perioperative hypertension management. Vasc Health Risk Manag 2008;4:615-627
33. Adis International Limited. Intravenous antihypertensives important in achieving blood pressure control in the perioperative setting. Drugs Ther Perspect 2008;24:9-12
34. Levy JH. Treatment of perioperative hypertension. Anesthesiol Clin North Am 1999;17:567-579
35. The Medicines Company Cleviprex- (Clevidipine Butyrate) injectable emulsion for intravenous use: US prescribing information [online] Available from: http// www.cleviprex.com/media/ClevidipinePI. pdf [Last accessed 16 September 2009]
36. CDER New Molecular Entity (NME) Drug and New Biologic Approvals for Calendar Year 2008 FDA Public Health Advisory. Washington, DC: FDA/Center for Drug Evaluation and Research, 2008. Available from: http://www.fda.gov/ downloads/Drugs/ DevelopmentApprovalProcess/ HowDrugsareDevelopedandApproved/ DrugandBiologicApprovalReports/ NMEDrugandNewBiologicApprovals/ UCM081805.pdf [Last accessed 16 September 2009]
37. Nordlander M, Sjöquist P, Ericsson H, et al.. Pharmacodynamic, pharmacokinetic and clinical effects of clevidipine, an ultrashort-acting calcium antagonist for rapid blood pressure control. Cardiovasc Drug Rev 2004;22:227-250
38. Noviawaty I, Uzun G, Qureshi AI. Drug evaluation of clevidipine for acute hypertension. Expert Opin Pharmacother 2008;9:2519-2529
39. Sorbera LA, Castanera J. Clevidipine. Drugs Future 2004;29:105-111
40. Ericsson H, Fakt C, Jolin-MellgårdA - , et al.. Clinical and pharmacokinetic results with a new ultrashort-acting calcium antagonist, clevidipine, following gradually increasing intravenous doses to healthy volunteers. Br J Clin Pharmacol 1999;47:531-538
41. Ericsson H, Fakt C, Höglund L, et al.. Pharmacokinetics and pharmacodynamics of clevidipine in healthy volunteers after intravenous infusion. Eur J Clin Pharmacol 1999;55:61-67
42. Prlesi L, Cheng-Lai A. Clevidipine: a novel ultra-short-acting calcium antagonist. Cardiol Rev 2009;17:147-152
43. Ericsson H, Bredberg U, Eriksson U, et al.. Pharmacokinetics and arteriovenous differences in clevidipine concentration following a short- and a long-term intravenous infusion in healthy volunteers. Anesthesiology 2000;92:993-1001
44. Schwieler JH, Ericsson H, Löfdahl P, et al.. Circulatory effects and pharmacology of clevidipine, a novel ultra short acting and vascular selective calcium antagonist, in hypertensive humans. J Cardiovasc Pharmacol 1999;34:268-274
45. Ericsson H, Schwieler J, Lindmark B, et al.. Enantioselective pharmacokinetics of the enantiomers of clevidipine following intravenous infusion of the racemate in essential hypertensive patients. Chirality 2001;13:130-134
46. Kieler-Jensen N, Jolin-Mellgård A - , Nordlander M, et al.. Coronary and systemic hemodynamic effects of clevidipine, an ultra-short-acting calcium antagonist, for treatment of hypertension after coronary artery surgery. Acta Anaesthesiol Scand 2000;44:186-193
47. Bailey JM, Lu W, Levy JH, et al.. Clevidipine in adult cardiac surgical patients. Anesthesiology 2002;96:1086-1094
48. Powroznyk AVV, Vuylsteke A, Naughton C, et al.. Comparison of clevidipine with sodium nitroprusside in the control of blood pressure after coronary artery surgery. Eur J Anaesthesiol 2003;20:697-703
49. Levy JH, Manacao MY, Gitter R, et al.. Clevidipine effectively and rapidly controls blood pressure preoperatively in cardiac surgery patients: the results of the randomized, placebo-controlled efficacy study of clevidipine assessing its preoperative antihypertensive effect in cardiac surgery-1. Anesth Analg 2007;105:918-925
50. Singla N, Warltier DC, Gandhi SD, et al.. Treatment of acute postoperative hypertension in cardiac surgery patients; an efficacy study of clevidipine assessing its postoperative antihypertensive effect in cardiac surgery-2 (ESCAPE-2), a randomized double-blind, placebo-controlled trial. Anesth Analg 2008;107:59-67
51. Aronson S, Cornelius CM, Stierer KA, et al.. Comparative studies of clevidipine to nitroglycerin, sodium nitroprusside, and nicardipine for scute hypertension treatment in cardiac surgery patients: the ECLIPSE trials. Anesth Analg 2008;107:1110-1121
52. Pollack CV, Varon J, Garrison NA, et al.. Clevidipine, an intravenous dihydropyridine calcium channel blocker, is safe and effective for the treatment of patients with acute severe hypertension. Ann Emerg Med 2009;53:329-338
53. Graffagnino C, Bergese SD, Love J, et al..; on behalf of the ACCELERATE Investigators. Clevidipine rapidly and safely reduces blood pressure in patients with acute intracerebral hemorrhage: interim results of the 'ACCELERATE' trial. 7th Neurocritical Care Society Meeting, Hilton New Orleans Riverside, New Orleans, LA, 11 - 14 November 2009
54. Zhang H. Clevidipine The Medicines Company. Curr Opin Investig Drugs 2002;3:1474-1478
55. Kenyon KW. Clevidipine: an ultra short-acting calcium channel antagonist for acute hypertension. Ann Pharmacother 2009;43:1258-1268
56. Deeks ED, Keating GM, Keam SJ. Clevidipine: a review of its use in the management of acute hypertension. Am J Cardiovasc Drugs 2009;9:117-134
57. Chatzizisis YS, Coskun AU, Jonas M, et al.. Role of endothelial shear stress in the natural history of coronary atherosclerosis and vascular remodeling: molecular, cellular, and vascular behavior. J Am Coll Cardiol 2007;49:2379-2393
58. Bailey RR. Labetalol in the treatment of patients with hypertension and renal function impairment. Br J Clin Pharmacol 1979;8(Suppl 2):135-40S
59. Chien S, Li S, Shyy YJ. Effects of mechanical forces on signal transduction and gene expression in endothelial cells. Hypertension 1998;31:162-169
60. Vaughan CJ, Delanty N. Hypertensive emergencies. Lancet 2000;356:411-417
61. Devereaux PJ, Goldman L, Yusuf S, et al.. Surveillance and prevention of major perioperative ischemic cardiac events in patients undergoing noncardiac surgery: a review. CMAJ 2005;173:779-788
62. Oparil S, Aronson S, Deeb GM, et al.. Fenoldopam: a new parenteral antihypertensive: consensus roundtable on the management of perioperative hypertension and hypertensive crises. Am J Hypertens 1999;12:653-664
63. Vuylsteke A, Feneck RO, Jolin-Mellgård A, et al.. Perioperative blood pressure control: a prospective survey of patient management in cardiac surgery. J Cardiothorac Vasc Anesth 2000;14:269-273
64. Calhoun DA, Oparil S. Treatment of hypertensive crisis. N Engl J Med 1990;323:1177-1183
65. Cheung AT. Exploring an optimum intra/ postoperative management strategy for acute hypertension in the cardiac surgery patient. J Card Surg 2006;21 (Suppl 1):S8-14
66. Weitz HH. Perioperative cardiac complications. Med Clin North Am 2001;85:1151-1169
67. Aronson S, Boisvert D, Lapp W. Isolated systolic hypertension is associated with adverse outcomes from coronary artery bypass grafting surgery. Anesth Analg 2002;94:1079-1084
68. Katz JN, Gore JM, Amin A, et al.. Practice patterns, outcomes, and end-organ dysfunction for patients with acute severe hypertension: the Studying the Treatment of Acute hypertension (STAT) registry. Am Heart J 2009;158:599-606.
69. Ericsson H, Bredberg U, Eriksson U, et al.. Pharmacokinetics and arteriovenous differences in clevidipine concentration following short- and a long-term intravenous infusion in healthy volunteers. Anesthesiology 2000;92:993-1001